Premium
Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease
Author(s) -
Sramek John J.,
Zarotsky Victoria,
Cutler Neal R.
Publication year - 2002
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.10087
Subject(s) - acetylcholinesterase , tolerability , cholinesterase , disease , acetylcholine , pharmacology , tacrine , drug development , alzheimer's disease , drug , cholinergic , medicine , clinical trial , adverse effect , neurotransmitter , acetylcholinesterase inhibitor , psychology , neuroscience , chemistry , central nervous system , enzyme , biochemistry
Researchers have for some time appreciated the role of the neurotransmitter acetylcholine in Alzheimer's disease, and have realized the development of a number of acetylcholinesterase inhibitors. Bridging and dynabridging studies have played an important role in the development of these agents. Several acetylcholinesterase inhibitors have demonstrated tolerability and efficacy in a number of clinical trials. The most common adverse events associated with acetylcholinesterase inhibitors are cholinergic in nature, namely nausea and vomiting. The various properties of the three acetylcholinesterase inhibitors in clinical use today provide the clinician with the only meaningful treatment choices for Alzheimer's disease (AD) at the present time. Drug Dev. Res. 56:347–353, 2002. Copyright © 2002 John Wiley & Sons, Ltd.